GSK Stock Analysis: Attractive Price For Incredible Dividend Yield

GSK Stock Analysis

Summary

  • GlaxoSmithKline’s stock price has fallen over the past year as its core performance struggles.gsk stock analysis
  • The price is now near its 52-week low, and is unlikely to fall much further limiting the risk involved with the stock.
  • Sales will improve next year, offering upside potential, and investors can enjoy the dividend yield until then.
  • I Know First Algorithm is bullish on this stock for the long-term, believing it is perfect for patient, income-seeking investors.

GlaxoSmithKline (NYSE: GSK) is a pharmaceutical company incorporated in the United Kingdom. The company researches and develops pharmaceutical drugs, vaccines, and consumer healthcare products, and it is well known in the biotech sector for its large dividend yield. A premier pharmaceutical company, its stock price has come under pressure over the last year, falling almost 23%.

Current prices are an extremely attractive value for potential investors, as prices have likely bottomed out before increasing next year when its new pipeline and restructuring improve its core performance. With such a strong dividend yield at a more than reasonable price, now is a great time to purchase this stock and be one of the investors that the company places an emphasis on returning value to going forward. I Know First has a bullish algorithmic forecast for this stock along with the bullish fundamental analysis.

Read The Full Seeking Alpha Article